71 assets in Relapsing-Remitting Multiple Sclerosis

Therapeutic assets addressing Relapsing-Remitting Multiple Sclerosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fingolimod Relapsing-Remitting Multiple Sclerosis	TG Therapeutics, Inc.	P4	BBB (79)
Glatiramer Relapsing-Remitting Multiple Sclerosis	University Hospital, Montpellier	P4	BBB (79)
Natalizumab Relapsing-Remitting Multiple Sclerosis	Biogen	P4	BBB (79)
Interferon ?1 (Human Fibroblast Protein Moiety) Relapsing-Remitting Multiple Sclerosis	Biogen	P4	BBB (77)
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER Relapsing-Remitting Multiple Sclerosis	University Hospital, Montpellier	P4	BBB (76)
Cladribine Relapsing-Remitting Multiple Sclerosis	Uppsala University	P4	BBB (76)
Ocrelizumab Relapsing-Remitting Multiple Sclerosis	Biocad	P4	BBB (76)
Peginterferon Beta-1A Relapsing-Remitting Multiple Sclerosis	Biogen	P4	BBB (75)
Humax-Cd20 Relapsing-Remitting Multiple Sclerosis	University Hospital, Montpellier	P4	BBB (74)
Teriflunomide Relapsing-Remitting Multiple Sclerosis	University Hospital, Montpellier	P4	BBB (74)
Alemtuzumab Relapsing-Remitting Multiple Sclerosis	Universitätsklinikum Hamburg-Eppendorf	P4	BBB (73)
Ozanimod Relapsing-Remitting Multiple Sclerosis	Bristol-Myers Squibb	P4	BB (70)
Quadrivalent Inactivated Influenza Vaccine Relapsing-Remitting Multiple Sclerosis	Novartis Pharmaceuticals	P4	BB (69)
Tolebrutinib Relapsing-Remitting Multiple Sclerosis	Sanofi	P3	BB (68)
Dexasone Relapsing-Remitting Multiple Sclerosis	Hoffmann-La Roche	P3	BB (66)
Ublituximab Relapsing-Remitting Multiple Sclerosis	TG Therapeutics, Inc.	P4	BB (66)
Rituximab Relapsing-Remitting Multiple Sclerosis	University Hospital, Montpellier	P3	BB (64)
Siponimod Relapsing-Remitting Multiple Sclerosis	Novartis Pharmaceuticals	P3	BB (64)
Ppsv23 Relapsing-Remitting Multiple Sclerosis	Celgene	P3	B (63)
Bms-986374 Relapsing-Remitting Multiple Sclerosis	Bristol-Myers Squibb	P4	B (62)
Fenebrutinib Relapsing-Remitting Multiple Sclerosis	Hoffmann-La Roche	P3	B (62)
Remibrutinib Relapsing-Remitting Multiple Sclerosis	Moein Amin	P3	B (62)
Vidofludimus Relapsing-Remitting Multiple Sclerosis	Immunic AG	P3	B (62)
Clemastin Relapsing-Remitting Multiple Sclerosis	University of California, San Francisco	P2	B (61)
Abp 692 Relapsing-Remitting Multiple Sclerosis	Amgen	P3	B (60)
Bcd-281 Relapsing-Remitting Multiple Sclerosis	Biocad	P3	B (60)
Ct-P53 Relapsing-Remitting Multiple Sclerosis	Celltrion	P3	B (60)
Cyclophosphamide Relapsing-Remitting Multiple Sclerosis	Scripps Health	P3	B (60)
Desloratadine Relapsing-Remitting Multiple Sclerosis	Hoffmann-La Roche	P3	B (60)
Fexofenadine Relapsing-Remitting Multiple Sclerosis	Rigshospitalet, Denmark	P3	B (60)
PCV 13 Relapsing-Remitting Multiple Sclerosis	Novartis Pharmaceuticals	P3	B (60)
Tetanus Toxoid Relapsing-Remitting Multiple Sclerosis	Celgene	P3	B (60)
Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Relapsing-Remitting Multiple Sclerosis	Celgene	P3	B (60)
Diphtheria Toxoid Relapsing-Remitting Multiple Sclerosis	Celgene	P3	B (59)
Keyhole Limpet Hemocyanin Relapsing-Remitting Multiple Sclerosis	Novartis Pharmaceuticals	P3	B (58)
cyb704 Relapsing-Remitting Multiple Sclerosis	Sandoz	P3	B (57)
Metformin Relapsing-Remitting Multiple Sclerosis	German University in Cairo	P2	B (57)
Mitoxantrone Relapsing-Remitting Multiple Sclerosis	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	P2	B (57)
Pipe-307 Relapsing-Remitting Multiple Sclerosis	Contineum Therapeutics	P2	B (57)
Diphenhydramine Relapsing-Remitting Multiple Sclerosis	Hoffmann-La Roche	P3	B (56)
Autologous Hb-Admscs Relapsing-Remitting Multiple Sclerosis	Hope Biosciences Research Foundation	P2	CCC (53)
Autologous Tolerogenic Dendritic Cells Relapsing-Remitting Multiple Sclerosis	Judit Pich	P2	CCC (53)
Dimethyl Trisulfide Relapsing-Remitting Multiple Sclerosis	Sichuan Academy of Medical Sciences	P2	CCC (53)
Ifenprodil Relapsing-Remitting Multiple Sclerosis	Assistance Publique - Hôpitaux de Paris	P2	CCC (53)
Imu-838 Relapsing-Remitting Multiple Sclerosis	Immunic AG	P2	CCC (53)
Interferon Beta 1 Relapsing-Remitting Multiple Sclerosis	Novartis Pharmaceuticals	P2	CCC (53)
Lispro-Ph20 Component Rhuph20 Relapsing-Remitting Multiple Sclerosis	Hoffmann-La Roche	P2	CCC (53)
Nebido® Testosterone Undecanoate / For Relapsing-Remitting Multiple Sclerosis	University Hospital, Strasbourg, France	P2	CCC (53)
Obexelimab Relapsing-Remitting Multiple Sclerosis	Zenas BioPharma (USA), LLC	P2	CCC (53)
Ocrelizumab Co-Formulated With Rhuph20 Relapsing-Remitting Multiple Sclerosis	Hoffmann-La Roche	P2	CCC (53)

Showing 1 to 50 of 71 assets

PreviousPage 1 of 2Next